Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests
Related to this article
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Scams: What Psychiatrists Need to Know
2
Preventing Schizophrenia Relapse in Women: What You Need to Know
3
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
4
A Veterans Day Salute: Lessons From 1918 and 2026 for Psychiatrists
5